Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Non-randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function

NCT04643795 is registered in ClinicalTrials.gov with Madrigal Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04643795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04643795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Non-randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2018
Completion date
August 4, 2021
Enrollment
87 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, hepatic impairment, nash - nonalcoholic steatohepatitis